Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial by Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song

Get full text

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialResearch in context by Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John G. Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil

Get full text

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium by Jonathan R. Day, Melissa C. Larson, Urshila Durani, Jean L. Koff, Yucai Wang, Thomas M. Habermann, Izidore S. Lossos, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, John P. Leonard, Jonathon B. Cohen, Brad S. Kahl, Jia Ruan, W. Richard Burack, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Matthew J. Maurer, Carla Casulo

Get full text

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

Get full text